Rota DD, Emeksiz MC, Erdogan FG, et al. - Given that alopecia areata (AA) and generalized form, universalis (AU) are prevalent causes of non‐cicatricial alopecia, targeting anagen hair follicles, researchers conducted this retrospective pilot study to evaluate oral tofacitinib's safety and effectiveness in 13 recalcitrant AA and AU patients. Thirteen patients with recalcitrant alopecia areata (3 AA, 10 AU), aged 17-49, were included in the study. Findings suggested that tofacitinib seems to be more successful and flourishing than AU for the treatment of AA. It may bring more good outcomes to start the therapy sooner. Unfortunately, even in cases that respond entirely to treatment, following discontinuation of treatment, relapse may be observed. To mitigate frustrations that can arise later, it is important to educate patients about this situation.